9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $36M | -$18M | 0.0% | -34.2% | -$18M | $0 | $30M |
| 2024 | $8M | -$77M | 65.6% | -871.3% | -$61M | $31M | $46M |
| 2023 | — | -$67M | — | — | -$39M | $43M | $70M |
| 2022 | — | -$24M | — | — | -$19M | $0 | $34M |
| 2021 | — | -$35M | — | — | -$28M | — | $16M |
| 2020 | — | -$43M | — | — | -$32M | — | $11M |
| 2019 | — | -$28M | — | — | -$28M | — | $9M |
| 2018 | — | -$21M | — | — | -$19M | — | $10M |
| 2017 | — | -$4M | — | — | — | — | $9M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $5M | -$10M | 0.0% | -193.4% | — | — | $21M |
| Dec '25 | $5M | -$8M | 0.0% | -141.2% | -$5M | $0 | $30M |
| Sep '25 | $14M | -$274000 | 0.0% | 11.3% | $10M | $22M | $21M |
| Jun '25 | — | $204000 | — | — | — | $25M | $15M |
| Mar '25 | $3M | -$10M | 79.6% | -236.4% | — | $28M | $30M |
| Dec '24 | $344000 | -$16M | -132.6% | -3316.9% | -$16M | $31M | $46M |
| Sep '24 | -$2M | -$23M | 122.5% | 1162.5% | -$9M | $43M | $23M |
| Jun '24 | — | -$17M | — | — | -$16M | $43M | $32M |
| Mar '24 | — | -$20M | — | — | -$20M | $43M | $49M |
| Dec '23 | — | -$25M | — | — | -$15M | $43M | $70M |
| Sep '23 | — | -$25M | — | — | -$15M | $42M | $84M |
| Jun '23 | — | -$11M | — | — | -$5M | — | $55M |
| Mar '23 | — | -$7M | — | — | -$5M | — | $60M |
| Dec '22 | — | -$6M | — | — | -$5M | $0 | $34M |
| Sep '22 | — | $83000 | — | — | $2M | — | $32M |
| Jun '22 | — | -$10M | — | — | -$7M | — | $5M |
| Mar '22 | — | -$8M | — | — | -$8M | — | $10M |
| Dec '21 | — | -$10M | — | — | -$9M | — | $16M |
| Sep '21 | — | -$13M | — | — | -$11M | — | $20M |
| Jun '21 | — | -$12M | — | — | $2M | — | $25M |
How the market has priced VRCA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Verrica Pharmaceuticals Inc.'s revenue has grown 370.2% per year. These are computed facts, not advice.
As of FY2025, Verrica Pharmaceuticals Inc. reported $0 of total debt against $30M of cash; operating income covered interest expense -1.6×.
In FY2025, gross margin was —, operating margin -34.2%, and net margin -50.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.